Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRα-expressing ewing sarcoma family of tumors and desmoplastic small round cell tumors

Anticancer Research

Volumn 30, Issue 2, 2010, Pages 547-552

  Chao, Joseph ^a   Budd, G Thomas ^b   Chu, Peiguo ^a   Frankel, Paul ^a   Garcia, Dolores ^a   Junqueira, Maribel ^a   Loera, Sofia ^a   Somlo, George ^a   Sato, Judith ^a   Chow, Warren A ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

DSRCT; Ewing sarcoma; Imatinib; KIT; PDGFR

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESMOPLASTIC SMALL ROUND CELL TUMOR; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; EWING SARCOMA; FEMALE; HUMAN; HUMAN TISSUE; HYPOKALEMIA; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ABDOMINAL NEOPLASMS; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CARCINOMA, SMALL CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROECTODERMAL TUMORS, PRIMITIVE; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SARCOMA, EWING'S; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77950547753     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Chow WA and Doroshow JH: The Ewing family of tumors (EFT) express the KIT and PDGFR-α tyrosine kinase receptors [abstract]. Proc AACR 43: 1668a, 2002.
2. Grier HE: The Ewing family of tumors. Ewing's sarcoma and primitive neuroectodermal tumors. Pediatr Clin North Am 44(4): 991-1004, 1997.
3. Granowetter L, Womer R, Devidas M et al: Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. J Clin Oncol 27(15): 2536-2541, 2009.
4. Wilkins RM, Pritchard DJ, Burgert EO Jr et al: Ewing's sarcoma of bone. Experience with 140 patients. Cancer 58(11): 2551-2555, 1986.
5. Ahrens S, Hoffmann C, Jabar S et al: Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localized Ewing sarcoma of bone: the CESS 86 experience. Cooperative Ewing Sarcoma Study. Med Pediatr Oncol 32(3): 186-195, 1999.
6. Vlasak R and Sim FH: Ewing's sarcoma. Orthop Clin North Am 27(3): 591-603, 1996.
7. Antman K, Crowley J, Balcerzak SP et al: A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. Cancer 82(7): 1288-1295, 1998.
8. Gobel V, Jurgens H, Etspuler G et al: Prognostic significance of tumor volume in localized Ewing's sarcoma of bone in children and adolescents. J Cancer Res Clin Oncol 113(2): 187-191, 1987.
9. Grier HE, Krailo MD, Tarbell NJ et al: Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 348(8): 694-701, 2003.
10. Bond M, Bernstein ML, Pappo A et al: A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer 50(2): 254-258, 2008.
11. Chugh R, Wathen JK, Maki RG et al: Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol 27(19): 3148-3153, 2009. Epub 2009 May 18.
12. Ricotti E, Fagioli F, Garelli E et al: c-Kit is expressed in soft tissue sarcoma of neuroectodermic origin and its ligand prevents apoptosis of neoplastic cells. Blood 91(7): 2397-2405, 1998.
13. Landuzzi L, De Giovanni C, Nicoletti G et al: The metastatic ability of Ewing's sarcoma cells is modulated by stem cell factor and by its receptor c-kit. Am J Pathol 157(6): 2123-2131, 2000.
14. Zwerner JP and May WA: PDGF-C is an EWS/FLI induced transforming growth factor in Ewing family tumors. Oncogene 20(5): 626-633, 2001.
15. Li X, Ponten A, Aase K et al: PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat Cell Biol 2(5): 302-309, 2000.
16. Gilbertson DG, Duff ME, West JW et al: Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor. J Biol Chem 276(29): 27406-27414, 2001. Epub 2001 Apr 10.
17. Chow WA, Wilczynski SP and Doroshow JH: Receptor tyrosine kinase inhibition in Ewing's family of tumors [abstract]. Proc AACR 44: 4700a, 2003.
18. Merchant MS, Woo CW, Mackall CL et al: Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity. J Natl Cancer Inst 94: 1673, 2002.
19. Chow WA, Chu P and Doroshow JH: The Ewing's family of tumors (EFT) express the tyrosine kinase receptors, Kit and PDGF-R [abstract]. Proc Am Soc Clin Oncol 22: 2003 (abstr 3321)
20. Therasse P, Arbuck SG, Eisenhauer EA et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
21. Druker BJ: Taking aim at Ewing's sarcoma: is KIT a target and will imatinib work? J Natl Cancer Inst 94(22): 1660-1661, 2002.
22. Bozzi F, Tamborini E, Negri T et al: Evidence for activation of KIT, PDGFRα, and PDGFRβ receptors in the Ewing sarcoma family of tumors. Cancer 109(8): 1638-1645, 2007.
23. Heinrich MC, Corless CL, Demetri GD et al: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21(23): 4342-4349, 2003.
24. Demetri GD, van Oosterom AT, Garrett CR et al: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368: 1329-1338, 2006.
25. McDermott U, Ames RY, Iafrate AJ et al: Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. Cancer Res 69(9): 3937-3946, 2009.
26. BMS0354825, Bristol-Myers Squibb Investigator Brochure, Version no. 5, Version date: 26-Jan-2006. BMS Document Control No. 930003494.